To add to your comments, this failure makes Noxopharm even more valuable if we can only replicate DARRT 1 trial results, with 4 abscopal responses, lower PSA and better quality of life for patients by reducing pain and suffering.
The initial IONIC trial was only meant to have 2-3 trial sites now there are 6 participating now, and the fact that BMS is paying for everything i would say that they may be seeing some positive results otherwise why continue, 12 months in and adding 22 new patients with a total of 33 participating looks very promising.
IONIC may yet be a winner, page-3
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $18.94K | 171.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 66800 | 1 |
View Market Depth
| Last trade - 14.48pm 08/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |